In order to characterize the sensitivity of an analog of levodopa and a dopamine transporter ligand to detect defects in nigrostriatal function, the uptake of [(18)F]FDOPA and [(18)F]CFT was studied ex vivo in a rat model of Parkinson's disease. The brains of these rats were unilaterally lesioned with an intranigral injection of 6-hydroxydopamine. The lesioned animals were divided into three groups subject to their behavior after pharmacological challenges. Circling behavior was recorded after amphetamine, apomorphine, and L-DOPA challenge in order to predict lesion size. The spatial distribution of radioactivity after [(18)F]FDOPA or [(18)F]CFT injection in brain sections was determined with digital autoradiography. Regions of interest were left/right striatum, left/right substantia nigra, and cerebellum. The degree of unilateral lesion for each animal was confirmed by counting of nigral tyrosine hydroxylase-positive cell bodies. With both tracers the uptake in the lesioned side was lower than in the intact side in the striatum and in the substantia nigra. In conclusion, both tracers clearly demonstrated nigrostriatal dopaminergic hypofunction and correlated with the number of nigral dopaminergic neurons. However, [(18)F]FDOPA showed a much higher unspecific uptake of radioactivity, due to extensive metabolism; therefore, this tracer was less sensitive than the transporter tracer [(18)F]CFT to detect these defects.
Antibiotic dry cow therapy (aDCT) at the end of lactation is an effective mastitis control measure. Selective dry cow therapy means that only infected or presumedinfected cows are treated, instead of aDCT being used as a treatment for all cows. Because antibiotic resistance poses a global threat, livestock production is under increasing pressure to reduce antibiotic use. Changes in management should not, however, impair animal welfare or cause significant economic losses. Our objective was to compare milk yield and somatic cell count (SCC) between aDCT-treated and untreated cows in herds that used selective aDCT, taking into account risk factors for reduced yield and high SCC. The information source was 2015 to 2017 Dairy Herd Improvement data, with 4,720 multiparous cows from 172 Finnish dairy farms. The response variables were testday milk yield (kg/d) and naturally log-transformed composite SCC (×1,000 cells/mL) during the first 154 d in milk (DIM). The statistical tool was a linear mixed-effects model with 2-level random intercepts, cows nested within herds, and a first-order autoregressive [AR(1)] correlation structure. The overall proportion of aDCT-treated cows was 25% (1,176/4,720). Due to the interaction effect, SCC on the last test day prior to dry-off affected postcalving milk yield differently in aDCT-treated cows than in untreated cows. A higher SCC prior to dry-off correlated with a greater daily yield difference after calving between cows treated and untreated. The majority of cows had SCC < 200,000 cells/mL before dry-off, and as SCC before dry-off decreased, difference in yield between aDCT-treated and untreated cows decreased. Postcalving SCC was lower for aDCT-treated cows compared with untreated cows. To illustrate, for cows with an SCC of 200,000 cells/mL before dry-off, compared with untreated cows, aDCTtreated cows produced 0.97 kg/d more milk and, at 45 DIM, had an SCC that was 20,000 cells/mL lower.Higher late-lactation SCC and lactational mastitis treatments were associated with higher postcalving SCC. A dry period lasting more than 30 d was associated with higher yields but not with SCC. Our findings indicate that a missed aDCT treatment for a high-SCC cow has a negative effect on subsequent lactation milk yield and SCC, which emphasizes the importance of accurate selection of cows to be treated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.